Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, October 4, 2022
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
[ Tue, Oct 04th 2022
] - WOPRAI
Vikram Purohit Maintained (ARQT) at Buy with Increased Target to $49 on, Oct 4th, 2022
Vikram Purohit of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Increased Target from $46 to $49 on, Oct 4th, 2022.
Vikram has made no other calls on ARQT in the last 4 months.
There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Vikram
- Sean Kim of "JonesTrading" Initiated at Strong Buy and Held Target at $54 on, Thursday, September 22nd, 2022
- Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $46 on, Wednesday, September 7th, 2022
- Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, August 2nd, 2022
- David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $39 on, Tuesday, June 7th, 2022
